These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35156573)

  • 21. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based development of antagonists for chemokine receptor CXCR4.
    Zhang C; Hou T; Feng Z; Li Y
    Curr Comput Aided Drug Des; 2013 Mar; 9(1):60-75. PubMed ID: 22734712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting CXCR4 in HIV cell-entry inhibition.
    Steen A; Schwartz TW; Rosenkilde MM
    Mini Rev Med Chem; 2009 Dec; 9(14):1605-21. PubMed ID: 20088780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HIV-1 entry into cells.
    Copeland KF
    Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):107-12. PubMed ID: 18221139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Viral entry as therapeutic target. Current situation of entry inhibitors].
    Arenzana-Seisdedos F
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV type 1 tropism and inhibitors of viral entry: clinical implications.
    Weber J; Piontkivska H; Quiñones-Mateu ME
    AIDS Rev; 2006; 8(2):60-77. PubMed ID: 16848274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
    Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
    J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of CXCR4 internalization in the anti-HIV activity of stromal cell-derived factor-1α probed by a novel synthetically and modularly modified-chemokine analog.
    Dong CZ; Tian S; Madani N; Choi WT; Kumar S; Liu D; Sodroski JG; Huang Z; An J
    Exp Biol Med (Maywood); 2011 Dec; 236(12):1413-9. PubMed ID: 22101518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches.
    Cutinho PF; Roy J; Anand A; Cheluvaraj R; Murahari M; Chimatapu HSV
    J Biomol Struct Dyn; 2020 Apr; 38(6):1626-1648. PubMed ID: 31046644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004 - 2010.
    Singh IP; Chauthe SK
    Expert Opin Ther Pat; 2011 Feb; 21(2):227-69. PubMed ID: 21219250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular docking and physicochemical studies of 1,3-benzodioxole tagged Dacarbazine derivatives as an anticancer agent.
    Kharb S; Yadav S; Singh A; Sarkar A; Tomar R
    Artif Cells Nanomed Biotechnol; 2023 Dec; 51(1):520-530. PubMed ID: 37698454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting HIV-1 through molecular modeling and docking studies of CXCR4: leads for therapeutic development.
    Singh S; Malik BK; Sharma DK
    Chem Biol Drug Des; 2007 Mar; 69(3):191-203. PubMed ID: 17441905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
    Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV entry inhibitors: mechanisms of action and resistance pathways.
    Briz V; Poveda E; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Himalayan bioactive molecules as potential entry inhibitors for the human immunodeficiency virus.
    Kumar Bhardwaj V; Purohit R; Kumar S
    Food Chem; 2021 Jun; 347():128932. PubMed ID: 33465692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of CXCR4 and CCR5 expression by interleukin (IL)-4 and IL-13 is associated with inhibition of chemotaxis and human immunodeficiency Virus (HIV) type 1 replication but not HIV entry into human monocytes.
    Creery D; Weiss W; Graziani-Bowering G; Kumar R; Aziz Z; Angel JB; Kumar A
    Viral Immunol; 2006; 19(3):409-23. PubMed ID: 16987060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
    Panos G; Watson DC
    Crit Rev Microbiol; 2015; 41(4):473-87. PubMed ID: 24635642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.